These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 26725467

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women.
    Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Gilbert L, Martel C, Balser J.
    J Sex Med; 2014 Jul; 11(7):1766-85. PubMed ID: 24774442
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration.
    Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Bérubé R, Bélanger P, Berger L, Gilbert L, Martel C, Balser J.
    Menopause; 2009 Jul; 16(5):897-906. PubMed ID: 19436226
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
    Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, BSc AB, Martel C, Vaillancourt M, Balser J, Moyneur É, members of the VVA Prasterone Research Group.
    Menopause; 2018 Nov; 25(11):1339-1353. PubMed ID: 30358731
    [Abstract] [Full Text] [Related]

  • 7. Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks.
    Martel C, Labrie F, Archer DF, Ke Y, Gonthier R, Simard JN, Lavoie L, Vaillancourt M, Montesino M, Balser J, Moyneur É, other participating members of the Prasterone Clinical Research Group.
    J Steroid Biochem Mol Biol; 2016 May; 159():142-53. PubMed ID: 26972555
    [Abstract] [Full Text] [Related]

  • 8. Serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administration.
    Ke Y, Labrie F, Gonthier R, Simard JN, Bergeron D, Martel C, Vaillancourt M, Montesino M, Lavoie L, Archer DF, Balser J, Moyneur E, other participating Members of the Prasterone Clinical Research Group.
    J Steroid Biochem Mol Biol; 2015 Nov; 154():186-96. PubMed ID: 26291918
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
    Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur É, VVA Prasterone Research Group.
    Menopause; 2016 Mar; 23(3):243-56. PubMed ID: 26731686
    [Abstract] [Full Text] [Related]

  • 10. Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens.
    Labrie F, Martel C, Bérubé R, Côté I, Labrie C, Cusan L, Gomez JL.
    J Steroid Biochem Mol Biol; 2013 Nov; 138():359-67. PubMed ID: 23954500
    [Abstract] [Full Text] [Related]

  • 11. Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women.
    Portman DJ, Labrie F, Archer DF, Bouchard C, Cusan L, Girard G, Ayotte N, Koltun W, Blouin F, Young D, Wade A, Martel C, Dubé R, other participating members of VVA Prasterone Group.
    Menopause; 2015 Dec; 22(12):1289-95. PubMed ID: 25968836
    [Abstract] [Full Text] [Related]

  • 12. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy.
    Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J.
    Menopause; 2009 Dec; 16(5):907-22. PubMed ID: 19436225
    [Abstract] [Full Text] [Related]

  • 13. TX-004HR Improves Sexual Function as Measured by the Female Sexual Function Index in Postmenopausal Women With Vulvar and Vaginal Atrophy: The REJOICE Trial.
    Kingsberg SA, Derogatis L, Simon JA, Constantine GD, Graham S, Bernick B, Gasper G, Mirkin S.
    J Sex Med; 2016 Dec; 13(12):1930-1937. PubMed ID: 27692842
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study.
    Labrie F, Archer DF, Bouchard C, Girard G, Ayotte N, Gallagher JC, Cusan L, Baron M, Blouin F, Waldbaum AS, Koltun W, Portman DJ, Côté I, Lavoie L, Beauregard A, Labrie C, Martel C, Balser J, Moyneur É, Members of the VVA Prasterone Group.
    Maturitas; 2015 May; 81(1):46-56. PubMed ID: 25771041
    [Abstract] [Full Text] [Related]

  • 16. Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner.
    Labrie F, Montesino M, Archer DF, Lavoie L, Beauregard A, Côté I, Martel C, Vaillancourt M, Balser J, Moyneur E, other participating Members of the Prasterone Clinical Research Group.
    Climacteric; 2015 May; 18(6):817-25. PubMed ID: 26517756
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of intravaginal dehydroepiandrosterone (DHEA) for symptomatic women in the peri- or postmenopausal phase.
    Sauer U, Talaulikar V, Davies MC.
    Maturitas; 2018 Oct; 116():79-82. PubMed ID: 30244783
    [Abstract] [Full Text] [Related]

  • 18. The use of dehydroepiandrosterone in the treatment of hypoactive sexual desire disorder: a report of gender differences.
    Bloch M, Meiboom H, Zaig I, Schreiber S, Abramov L.
    Eur Neuropsychopharmacol; 2013 Aug; 23(8):910-8. PubMed ID: 23084789
    [Abstract] [Full Text] [Related]

  • 19. Prasterone: A Review in Vulvovaginal Atrophy.
    Heo YA.
    Drugs Aging; 2019 Aug; 36(8):781-788. PubMed ID: 31290076
    [Abstract] [Full Text] [Related]

  • 20. Comparison of intravaginal 6.5mg (0.50%) prasterone, 0.3mg conjugated estrogens and 10μg estradiol on symptoms of vulvovaginal atrophy.
    Archer DF, Labrie F, Montesino M, Martel C.
    J Steroid Biochem Mol Biol; 2017 Nov; 174():1-8. PubMed ID: 28323042
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.